CRTC2 (TORC2) Contributes to the Transcriptional Response to Fasting in the Liver but Is Not Required for the Maintenance of Glucose Homeostasis  by Le Lay, John et al.
Cell Metabolism
Short ArticleCRTC2 (TORC2) Contributes to the Transcriptional
Response to Fasting in the Liver but Is Not
Required for theMaintenanceofGlucoseHomeostasis
John Le Lay,1,3 Geetu Tuteja,1,3 Peter White,1,3 Ravindra Dhir,1,2 Rexford Ahima,1,2 and Klaus H. Kaestner1,3,*
1Department of Genetics
2Department of Medicine
3Institute for Diabetes, Obesity, and Metabolism
University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
*Correspondence: kaestner@mail.med.upenn.edu
DOI 10.1016/j.cmet.2009.06.006SUMMARY
The liver contributes to glucose homeostasis by
promoting either storage or production of glucose,
depending on the physiological state. The cAMP
response element-binding protein (CREB) is a prin-
cipal regulator of genes involved in coordinating the
hepatic response to fasting, but its mechanism of
gene activation remains controversial. We derived
CRTC2 (CREB-regulated transcription coactivator 2,
previously TORC2)-deficient mice to assess the
contributionof thiscofactor tohepaticglucosemetab-
olism in vivo. CRTC2 mutant hepatocytes showed
reduced glucose production in response to glucagon,
which correlated with decreased CREB binding to
several gluconeogenic genes. However, despite
attenuated expression of CREB target genes, in-
cluding PEPCK, G6Pase, and PGC-1a, no hypogly-
cemia was observed in mutant mice. Collectively,
these results provide genetic evidence supporting
a role for CRTC2 in the transcriptional response to
fasting, but indicate only a limited contribution of this
cofactor to the maintenance of glucose homeostasis.
INTRODUCTION
Maintenance of blood glucose levels within a relatively tight
range is of critical importance, as evidenced by the complica-
tions arising from diabetes or hyperinsulinism. The liver, a key
target of both insulin and glucagon signaling, contributes to the
control of glucose metabolism by facilitating glucose uptake
and output, depending on the physiologic condition (Pilkis and
Granner, 1992). Insulin is released from pancreatic b cells
when nutrient availability is high and instructs peripheral tissues,
such as liver and muscle, to remove glucose from the blood-
stream and store it for later use, effectively preventing prolonged
hyperglycemia. In times of food deprivation, however, the liver is
central in the metabolic response to glucagon, epinephrine, and
glucocorticoids, which act to stimulate hepatic glucose produc-
tion (HGP) via glycogenolysis and gluconeogenesis in order to
prevent extended periods of hypoglycemia.The gluconeogenic program is largely regulated at the level of
transcription, a process thought to be coordinated by the cAMP
response element-binding protein (CREB) and its ability to acti-
vate PPARg coactivator-1a (PGC-1a) (Herzig et al., 2001). Two
mechanisms have been proposed to explain how CREB
responds to glucagon and/or epinephrine stimulation in order
to elicit the appropriate changes in hepatic gene expression.
Originally, phosphorylation of CREB at serine 133 by the
cAMP-responsive protein kinase A (PKA) and the subsequent
recruitment of CREB-binding protein (CBP) or its paralog p300
were suggested to be the pivotal regulatory events (Chrivia
et al., 1993; Gonzalez and Montminy, 1989; Kwok et al., 1994;
Mayr and Montminy, 2001). CBP and p300 are cofactors that
promote gene transcription through their intrinsic histone deace-
tylase activity and through direct interactions with the basal tran-
scription machinery (Bannister and Kouzarides, 1996; Goodman
and Smolik, 2000; Shiama, 1997). More recently, the simplicity of
this model has been challenged with the discovery of the CREB-
regulated transcription coactivator (CRTC) family of cofactors
(Conkright et al., 2003; Iourgenko et al., 2003). CRTC2, also
called transducer of regulated CREB activity 2 (TORC2), is the
most abundant CRTC protein in the liver and has been implicated
as the foremost mediator driving CREB target gene expression
(Conkright et al., 2003; Koo et al., 2005). Upon glucagon stimula-
tion, cytoplasmic CRTC2 is dephosphorylated and translocates
to the nucleus, where it engages CREB in a phosphorylation-
independent manner to direct the gluconeogenic program
(Bittinger et al., 2004; Screaton et al., 2004). In attempts to unify
the two models, it has been suggested that CRTC2 is required in
addition to CREB phosphorylation for the proper recruitment
of CBP and p300 to regulatory complexes at CREB target
sequences (Ravnskjaer et al., 2007; Xu et al., 2007). However,
it has also been proposed that the transcriptional response to
fasting is only transiently dependent on CRTC2, with the demon-
stration that it is deacetylated and degraded after long-term food
deprivation, at which point FOXO1 takes over as the predomi-
nant transcriptional regulator (Liu et al., 2008).
In order to begin to address this complex issue using genetic
means, we assessed the hepatic response to fasting in mice
harboring a null mutation in the Crtc2 gene. Surprisingly,
CRTC2 null (CRTC2/) mice did not display fasting hypogly-
cemia despite impairments in the transcription of several meta-
bolic genes. These transcriptional defects were observed onlyCell Metabolism 10, 55–62, July 8, 2009 ª2009 Elsevier Inc. 55
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to regulate gene expression beyond the short term. We also
show that CREB association with target sequences, although
unchanged during the initial stages of fasting, is reduced in the
livers of 24 hr-fasted CRTC2/ mice, possibly accounting for
the observed transcriptional deficiencies. Collectively, our results
indicate a supporting role for CRTC2 in the regulation of CREB
target genes in response to fasting but challenge its status as
the key mediator of the gluconeogenic program.
RESULTS AND DISCUSSION
Derivation of the CRTC2/ Allele
To assess CRTC2 function in vivo, we derived a CRTC2/ allele
via homologous recombination in mouse embryonic stem cells.
The targeting strategy used to construct this mutant allele is
shown in Figure 1A. loxP sites were positioned upstream of
exon 3 and downstream of exon 11 to force deletion of the
sequence spanning exon 4 to exon 11 of the Crtc2 gene upon
exposure to Cre recombinase. Crosses to the ubiquitous EIIa-
Cre line resulted in recombination between loxP sites in the
germline, yielding a global null allele. Western blotting confirmed
the effective deletion of the full-length Crtc2 gene product
(Figure 1B). CRTC2/ animals were born at the expected
Mendelian frequency, gained weight appropriately with age,
and were generally indistinguishable from littermate controls
(data not shown). The livers of adult CRTC2/ mice also ap-
peared histologically normal (data not shown). In addition, there
were no appreciable differences in most plasma metabolic
parameters of fasted CRTC2 mutant mice compared to controls,
except for a small but significant decrease in corticosterone
levels (Table S1).
CRTC2 Contributes to the Regulation of Genes Involved
in the Hepatic Response to Fasting
CRTC2 has been described as a critical component of the early
transcriptional fasting response in the liver (Koo et al., 2005; Liu
et al., 2008). When circulating glucose and insulin levels are low,
glucagon and/or epinephrine signaling in hepatocytes results in
the dephosphorylation of CRTC2 and its translocation to the
nucleus, where it drives the transcription of several genes impor-
tant in gluconeogenesis. Following long-term stimulation,
however, it has been proposed that CRTC2 is deacetylated
and targeted for degradation in the proteasome (Liu et al.,
2008). CRTC2 activity is further controlled by insulin signaling,
which results in CRTC2 phosphorylation and exclusion from
the nucleus, where it can no longer impact gene expression
(Dentin et al., 2007). Thus, in the absence of CRTC2, hypogly-
cemia due to impaired HGP would occur during the initial stages
of fasting. To test this hypothesis, blood glucose measurements
were taken from CRTC2/ mice along with littermate controls at
regular intervals during a 24 hr fasting time course. As expected,
no difference in blood glucose levels was observed in mice fed
ad libitum (Figures 2A and 2B). Strikingly, we also found no differ-
ences between groups at any time point measured during the
24 hr fast (Figures 2A and 2B). Furthermore, glucose production
following injection of a pyruvate bolus was not affected in mutant
mice (Figure 2C). Finally, hepatic glucose production as deter-
mined by radioisotopic tracer techniques before or during56 Cell Metabolism 10, 55–62, July 8, 2009 ª2009 Elsevier Inc.Figure 1. Derivation of the CRTC2/ Mouse
(A) loxP sites were positioned to flank exon 4 and exon 11 of the Crtc2 gene as
well as a Neomycin (Neo) selection cassette. Mice harboring the CRTC2 loxP
allele were crossed to EIIa-Cre transgenic mice, resulting in a null allele lacking
the loxP-flanked exons and the Neomycin selection cassette.
(B) Western blot analysis of whole-cell liver lysates taken from mice homozy-
gous for the null allele (/) or littermate controls (+/+). Livers were dissected
from mice fed ad libitum or fasted for the amount of time indicated.
(C) Quantitative RT-PCR to measure relative CRTC1 mRNA levels in the liver of
control (+/+) and CRTC2/ (/) mice fasted for the indicated amount of time
or allowed to feed ad libitum (fed). Transcript levels in control mice were
assigned an arbitrary value of 1.0 for comparison. n = 5 for each group. Values
are presented as average ± SD.
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Limited Role for CRTC2 in Glucose MetabolismFigure 2. CRTC2 Knockout Mice Maintain Normal Fed and Fasting Glycemia
(A and B) Blood glucose levels of control (+/+) and CRTC2/ (/) mice during the course of a 24 hr fast. n = 8–12 for each group.
(C) Blood glucose levels of control (+/+) and CRTC2/ (/) mice after overnight fasting (0 min) and following injection of a pyruvate bolus at the times indicated.
n = 6 for each group.
(D) Hepatic glucose production (HGP) was measured before (Basal HGP) and during a hyperinsulinemic-hypoglycemic clamp. Glucose infusion rate (GIR) and
glucose disposal (Rd) were also measured during the clamp. n = 4 for each group. Values are presented as average ± SD.hyperinsulinemic-hypoglycemic clamps was not statistically
different between CRTC2 mutants and littermate controls (Fig-
ure 2D). Collectively, these results indicate that CRTC2 is not
required to maintain the appropriate physiological response to
fasting.
Next, we examined the hepatic mRNA expression levels of
G6Pase, PEPCK, and PGC-1a, three cAMP-inducible genes
involved in the response to fasting (Yoon et al., 2001). As ex-
pected, gene expression levels were indistinguishable in animals
that were refed following an overnight fast or allowed to feed ad
libitum (Figure 3A). Despite the apparently normal glucose
homeostasis of CRTC2/ animals, the expression of G6Pase,
PEPCK, and PGC-1a was moderately but significantly reduced
in CRTC2 mutants, but only after a prolonged 24 hr fast (Fig-
ure 3A). In light of the recent report implicating a role for
CRTC2 primarily in the early phases of fasting (Liu et al., 2008),
it is worth noting that the timing of these transcriptional defi-
ciencies suggests the continued contribution of CRTC2 to the
control of gene expression in the long term. In accordance with
this finding, total CRTC2 protein remained abundant in the liver
even following the 24 hr fast when we expected it to be absent
due to degradation (Figure 1B). Protein levels of FOXO1,
CREB, serine 133-phosphorylated CREB, STAT3, HNF4a, C/
EBPa, and C/EBPb were similar in the livers of control and
mutant mice, indicating that these factors are not likely to
compensate for the lack of CRTC2 in the short term (Figure 1B).
Furthermore, CRTC1 message levels were unaltered by the loss
of CRTC2 activity (Figure 1C). These experiments demonstratethat, despite its involvement in the regulation of G6Pase, PEPCK,
and PGC-1a, CRTC2 is not required for an adequate metabolic
response to hypoglycemia.
Hepatocyte Function Is Impaired by CRTC2 Deficiency
Many mechanisms in multiple tissues are in place to help
respond to metabolic challenges. During a fast, blood glucose
levels are maintained through the coordinated efforts of glyco-
genolysis and gluconeogenesis and, ultimately, the shift from
glucose utilization to fatty acids and ketones as substrates for
energy production (Wang et al., 2006). Despite having compro-
mised expression of several genes involved in the hepatic
response to fasting, no overt glycemic phenotype was observed
in CRTC2/ mice. Indeed, similar outcomes have been ob-
served upon deletion of other metabolic genes, including PEPCK
and PGC-1a, which also fail to elicit dramatic metabolic pheno-
types (Leone et al., 2005; She et al., 2000). Based on our expres-
sion analysis indicating that several key genes involved in gluco-
neogenesis are impacted by CRTC2 deletion, we suspected that
hepatocytes in mutant animals might have functional impair-
ments that are masked by compensation in other tissues when
we analyzed glucose homeostasis in vivo. To address this point,
hepatocytes from control and mutant mice were isolated and as-
sayed in culture. As expected, the induction of G6Pase, PEPCK,
and PGC-1a mRNA levels in response to glucagon stimulation,
as a surrogate for fasting, was blunted in CRTC2 mutant hepato-
cytes (Figure 3B). Notably, the induced expression of these
genes was impaired to a greater extent in culture than we hadCell Metabolism 10, 55–62, July 8, 2009 ª2009 Elsevier Inc. 57
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Limited Role for CRTC2 in Glucose MetabolismFigure 3. The Transcriptional Response to Fasting Is Blunted in CRTC2/ Hepatocytes
(A) Quantitative RT-PCR to measure relative G6Pase, PEPCK, and PGC-1a mRNA levels in the liver of control (+/+) and CRTC2/ (/) mice fasted for the
indicated amount of time, refed following an overnight fast (refed), or allowed to feed ad libitum (fed).
(B) Quantitative RT-PCR to measure relative G6Pase, PEPCK, and PGC-1a mRNA levels in primary hepatocytes isolated from control (+/+) and CRTC2/ (/)
mice 2 hr after treatment with 50 nM glucagon. Transcript levels in control cells were assigned an arbitrary value of 1.0 for comparison.
(C) Glucose levels were measured in the culture medium of primary hepatocytes isolated from control (+/+) and CRTC2/ (/) mice 5 hr after treatment with or
without 50 nM glucagon. n = 6–10 for each group.
(D and E) Glycogen levels were measured in liver and muscle taken from mice allowed to feed ad libitum. n = 5 for each group. All values are presented as average
± SD. *p < 0.05.observed in the liver (Figure 2B), again implicating additional
mechanisms, such as activation by glucocorticoids, that may
be at play in the whole animal to maintain sufficient hepatic ex-
pression of these relevant transcripts. Furthermore, CRTC2/
hepatocytes failed to secrete as much glucose as controls
following glucagon stimulation (Figure 3C), indicating a func-
tional impairment that is presumably overcome by additional
processes unaffected by CRTC2 deletion in vivo. Indeed, we
observed that liver and muscle glycogen levels were significantly
reduced in fed CRTC2 mutants (Figures 3D and 3E). This obser-
vation could be indicative of an unrecognized role for CRTC2 in
regulating glycogen metabolism, but it may also represent
a mechanism by which hepatocytes and other tissues are able
to offset any insufficiencies provoked by the absence of CRTC2.
CREB Recruitment to Target Sequences Is Reduced
in the Absence of CRTC2
It has been suggested that CRTC2 imparts regulation on target
genes by specifically interacting with CREB and facilitating
recruitment of the coactivators CBP and p300 to CREB target
sequences (Liu et al., 2008; Ravnskjaer et al., 2007; Xu et al.,
2007). We therefore expected that the association of CBP or
p300 with PEPCK, PGC-1a, and G6Pase control regions would
be attenuated in the livers of CRTC2/ mice, thus resulting in58 Cell Metabolism 10, 55–62, July 8, 2009 ª2009 Elsevier Inc.their decreased expression. To test this hypothesis, we per-
formed chromatin immunoprecipitation (ChIP) assays on chro-
matin isolated from the livers of fasted CRTC2/ and control
mice. Strikingly, we found no significant differences in the ability
of CBP or p300 to interact with regulatory complexes at any of the
promoters tested (Figures 4A and 4B). Furthermore, despite
having previously been described as direct targets for CREB acti-
vation (Herzig et al., 2001; Schmoll et al., 1999; Waltner-Law
et al., 2003; Zhang et al., 2005), CREB binding to these promoter
regions was relatively weak and, in the cases of the PGC-1a and
G6Pase promoters, nearly undetectable (Figure 4C).
Based on these results, we hypothesized that previously un-
appreciated control sequences that confer CREB responsive-
ness to these metabolic genes may exist. To localize these
elements, we performed ChIP-Seq experiments on chromatin
prepared from the livers of fasted mice as an unbiased approach
toward the genome-wide identification of CREB target sites.
With a focus on the PEPCK, PGC-1a, and G6Pase loci, we
were able to identify cAMP response element (CRE)-containing
sequences strongly bound by CREB in vivo approximately
5.8 kb upstream of the PEPCK transcription start site (Figure 4D)
and in an intronic region approximately 8 kb downstream of
the PGC-1a promoter (Figure 4E). No new regions bound by
CREB were discovered upon examination of the G6Pase locus.
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Limited Role for CRTC2 in Glucose MetabolismFigure 4. Binding of CREB to Select Target Sequences Is Reduced in CRTC2 Knockout Hepatocytes
(A–C) ChIP assays were performed on chromatin isolated from the livers of CRTC2/ (/) or control (+/+) mice fasted for 6 or 24 hr using antibodies against
CBP (A), p300 (B), or CREB (C). Quantitative PCR was performed to determine enrichment of sequences associated with the PEPCK, G6Pase, and PGC-1a
genes. n = 5–9 for each group.
(D–E) Schematics of the PEPCK (D) and PGC-1a (E) genes, indicating the location of the unique CREB-binding regions as determined by ChIP-Seq analysis. The
distal PEPCK element is located at 5870 bp relative to its transcription start site, while the PGC-1a region is located at +8020 bp within intron 2. The CRE
sequences are underlined. Notice that peaks near the respective promoters, where presumptive CRE sequences have been described (arrowheads), are not
as pronounced, indicating enhanced CREB occupancy at the sites. All values are presented as average ± SEM. *p < 0.05.Robust CREB occupancy at these target sites in the PEPCK and
PGC-1a genes was confirmed by qPCR in chromatin isolated
from livers of fasted control mice (Figure 4C). While CBP and
p300 binding at these sites was similarly unaffected by the
absence of CRTC2 (Figure 4B), we found that CREB occupancy
at the PEPCK and PGC-1a target sequences was reduced inhepatocytes of CRTC2/ mice fasted for 24 hr (Figure 4C). In
accordance with the gene expression pattern, CREB binding
was not affected in the livers of mice fasted for 6 hr, thus
revealing a correlation between CREB binding and the transcrip-
tional activity of these genes. These data indicate a direct role for
CRTC2 in facilitating CREB binding to select target elements butCell Metabolism 10, 55–62, July 8, 2009 ª2009 Elsevier Inc. 59
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ated G6Pase regulation. Neither CBP nor p300 recruitment to
the G6Pase promoter region was impacted by the CRTC2 dele-
tion, while CREB binding to its presumptive CRE was tenuous,
leaving open the possibility of indirect or CREB-independent
mechanisms of control. Overall, these results support a role for
CRTC2 in regulating the expression of gluconeogenic genes in
the liver, but they also indicate that the overall contribution of
CRTC2 to glucose homeostasis in vivo is limited.
EXPERIMENTAL PROCEDURES
Derivation of CRTC2/ Mice
An 18.7 kb DNA fragment containing all CRTC2 coding sequences was
retrieved from C57BL/6J mouse bacterial artificial chromosome clone RP23-
237D16 via bacterial recombination (Copeland et al., 2001) into plasmid
PL253 that contains an Mc1-driven thymidine kinase cassette for negative
selection. One loxP site was inserted upstream of exon 3, while a pair of
loxP sites flanking a neomycin selection cassette were placed downstream
of exon 11, also by bacterial recombination. The linearized targeting vector
was electroporated into B6 embryonic stem cells (ESCs) (Chemicon; Billerica,
MA), and clones that survived G418 and ganciclovir selection were screened
for homologous recombination by Southern blot analysis. Targeted clones
were injected into C57BL/6J-derived blastocysts that were then transferred
to pseudopregnant females. Male offspring were mated to C57BL/6J females,
and ESC-derived offspring were identified by PCR-based genotyping. Mice
harboring the targeted insertion of the three loxP sites in the Crtc2 gene locus
were then crossed to the EIIa-Cre line to achieve germline deletion of loxP-
flanked sequences (Holzenberger et al., 2000). Mice heterozygous for the
CRTC2 deletion (CRTC2+/) were then mated to C57BL/6J to segregate
away the EIIa-Cre transgene. CRTC2+/ mice were then intercrossed to obtain
CRTC2/ animals. Genotyping of all offspring was performed by PCR using 50
and 30 primers for CRTC2 (50-GCCTGATTTTTCCCCCTATT-30 and 50-CATCT
CAATGAAGGCCACCT-30), which yield a 431 bp product from the wild-type
allele and a 608 bp product from the CRTC2/ allele. All PCR was performed
for 35 cycles under the following conditions: 95C, 30 s; 60C, 30 s; 72C, 60 s.
Plasma Metabolic Profile Analysis
Whole venous blood collected from the inferior vena cava of CRTC2/ and
control mice was applied to plasma separator tubes with lithium heparin anti-
coagulant (BD Biosciences) and centrifuged for 2 min at 14,0003 g, and the
plasma was collected. Metabolic parameters were determined by Ani Lytics,
Inc. (Gaithersburg, MD).
Whole-Cell Lysate Preparation and Western Blot Analysis
Liver fragments from CRTC2/ and control mice were homogenized by hand
in 200 ml of lysis buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.5% deoxycholic acid, and 1% SDS; supplemented
with protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 1
and 2 (Sigma); then sonicated using a Bioruptor (Diagenode; Sparta, NJ).
Whole-cell lysates were then centrifuged at maximum speed for 15 min to
pellet cellular debris, and the supernatant was collected. Protein concentra-
tions were determined by Bradford assay using Protein Assay Reagent (Bio-
Rad). Approximately 50 mg of whole-cell lysates were separated by SDS-
PAGE and transferred to Immobilon-P membranes (Millipore). Membranes
were blocked in buffer consisting of 5% milk and 0.1% Tween 20 in 13 PBS
(PBST milk) for 4 hr and then incubated overnight at 4C with anti-CRTC2
(ST1099, Calbiochem) diluted 1:5000, anti-FOXO1 (C29H4, Cell Signaling)
diluted 1:1000, anti-CREB (48H2, Cell Signaling) diluted 1:1000, anti-phos-
pho-CREB (87G3, Cell Signaling) diluted 1:1000, anti-HNF4a (H6939, R&D
Systems) diluted 1:1000, anti-STAT3 (9132, Cell Signaling) diluted 1:1000,
anti-C/EBPa (sc-61, Santa Cruz) diluted 1:500, anti-C/EBPb (sc-150, Santa
Cruz) diluted 1:500, or anti-b-actin (13E5, Cell Signaling) diluted 1:2000 in
PBST milk. After washing, membranes were incubated with HRP-conjugated
goat-anti-rabbit IgG (GE Healthcare Bio-Sciences Corp.; Piscataway, NJ)
diluted 1:12,500 in PBST milk for 45 min at RT. After washing, proteins were60 Cell Metabolism 10, 55–62, July 8, 2009 ª2009 Elsevier Inc.visualized using the ECL Plus Western Blotting Detection System (GE Health-
care Bio-Sciences Corp).
Determination of Blood Glucose Levels and Pyruvate Challenge
Blood was sampled from the tail vein of mice allowed to feed ad libitum (fed) or
fasted for 6, 9, 12, or 24 hr. Glucose levels were measured with a OneTouch
Ultra Glucometer (LifeScan; Milpitas, CA). For gene expression analyses of
refed animals, mice were fasted overnight and then allowed to feed for 2 hr
before sacrifice. For pyruvate challenge experiments, animals were fasted
overnight, and a blood glucose measurement was taken and considered
time 0. Mice were then injected intraperitoneally with 2 g of pyruvate
(Sigma-Aldrich) per kg of body weight. Glucose levels were then measured
at 15, 30, 60, 90, and 120 min postinjection.
Hyperinsulinemic-Hypoglycemic Clamp
Glucose homeostasis was measured in 12- to 15-week-old male control and
CRTC2/ mice using insulin clamp and radioisotopic tracer techniques (Alen-
ghat et al., 2008; Varela et al., 2008). An indwelling catheter was inserted in the
right internal jugular vein under sodium pentobarbital anesthesia and extended
to the right atrium. Four days after recovery, the mice were fasted overnight for
16 hr. They were placed in restrainers and administered a bolus injection of
5 mCi of [3-3H]glucose, followed by continuous intravenous infusion at
0.05 mCi/min. Baseline glucose kinetics were measured for 60 min, followed by
hyperinsulinemic-hypoglycemic clamp for 120 min. A priming dose of regular
insulin (16 mU/kg [Humulin, Eli Lilly; Indianapolis, IN]) was given intravenously,
followed by continuous infusion at 2.5 mU/kg1/min1. Blood glucose was
maintained at 60–70 mg/dl via a variable infusion rate of 20% glucose. The
mice were euthanized, and liver samples were excised, frozen immediately
in liquid nitrogen, and stored at 80C. The rates of basal glucose turnover
and whole-body glucose uptake are measured as the ratio of the [3H]glucose
infusion rate (GIR) (dpm) to the specific activity of plasma glucose. HGP during
clamp was measured by subtracting the GIR from the whole-body glucose
uptake (Rd).
Glycogen Assay
Tissue samples from mice fed ad libitum were homogenized in 6% PCA
(500 ml/100 mg tissue). Precipitates were pelleted, and the supernatant was
collected. One volume of H2O was added, and the solution was adjusted to
pH 6.5 with 10 N KOH. A fraction of each sample was then incubated with
five volumes of amyloglucosidase (1 mg/ml in 0.2 M [pH 4.8] acetate buffer)
at 40C for 2 hr. Glucose concentrations were then determined using the
Amplex Red Glucose/Glucose Oxidase Assay Kit (Invitrogen). Samples incu-
bated in the absence of amyloglucosidase were used as baseline controls.
RNA Isolation and Quantitative RT-PCR Analysis
Total cellular RNA was extracted from liver fragments or cultured primary
hepatocytes using RNeasy Kit (QIAGEN), then assayed for quantity and quality
with the Agilent 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA).
Approximately 1 mg of total RNA was reverse transcribed using oligo (dT)
and Superscript II Reverse Transcriptase (Invitrogen). The resulting cDNA
samples were the template for qPCR experiments performed with SYBR
GreenER qPCR Supermix (Invitrogen) and the SYBR Green (with dissociation
curve) program on the Mx3000 Multiplex Quantitative PCR System (Strata-
gene). Reactions were performed in triplicate and normalized relative to the
ROX reference dye. Median cycle threshold values were determined and
used for analyses. Expression levels were normalized to those of hypoxan-
thine-guanine phosphoribosyltransferase (HPRT) as the internal control.
Primer information is available at http://www.med.upenn.edu/kaestnerlab/
index.shtml.
Primary Hepatocyte Isolation and Culture
Hepatocytes were isolated from 3-month-old mice. The vena cava was cannu-
lated and the liver was perfused with 37C Liver Perfusion Buffer (GIBCO) for
2 min, then 50 ml of 37C Liver Digestion Buffer (GIBCO) supplemented with
30 mg of collagenase D (Roche). The liver was then excised, dispersed in
DMEM containing 10% FBS and penicillin/streptomycin, filtered through
a 100 mm mesh, pelleted, and subjected to a Percoll gradient (45% Percoll
in DMEM) to isolate viable cells. After two washes in DMEM containing 10%
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I-coated plates (BioCoat; Becton Dickinson; Franklin Lakes, NJ) at a density
of 150,000 cells/well in DMEM containing 10% FBS and penicillin/strepto-
mycin. For gene expression analysis, cells were cultured for 48 hr and then
stimulated with 50 nM glucagon for 2 hr before harvesting for RNA isolation.
For glucose production measurements, cells were cultured for 24 hr and
then switched to glucose-free medium containing 20 mM sodium lactate
and 2 mM sodium pyruvate before stimulating for 5 hr with 50 nM glucagon.
The culture medium was collected for glucose concentration determination
via Amplex Red Glucose/Glucose Oxidase Assay (Invitrogen).
ChIP-Seq and Quantitative RT-PCR Analysis
Chromatin from control and CRTC2/ livers was prepared as previously
described (Tuteja et al., 2008). Immunoprecipitations were also performed
as previously described (Tuteja et al., 2008), except that the herring sperm
DNA was excluded from the agarose bead blocking step. Sheared chromatin
(10 mg) was incubated overnight at 4C with 2 mg of anti-CREB (sc-186X, Santa
Cruz), anti-CBP (sc-369X and sc-583X, Santa Cruz), or anti-p300 (sc-584X and
sc-585X, Santa Cruz), and immune complexes were recovered with protein
G-conjugated agarose beads for 45 min at 4C. Enrichment of target DNA frag-
ments was determined via qPCR using SYBR GreenER qPCR Supermix (Invi-
trogen) and the SYBR Green (with dissociation curve) program on the Mx3000
Multiplex Quantitative PCR System (Stratagene). qPCR experiments were per-
formed in triplicate on both input (sheared genomic DNA) and ChIP sample
DNA, and median cycle threshold values were used for analysis. Enrichment
of bound regions was calculated using the myelin basic protein promoter
as a reference for nonspecific binding and comparing to amplification values
obtained from input DNA.
For ChIP-Seq experiments, the remainder of the immunoprecipitated DNA
was modified for sequencing following the manufacturer’s protocol (Illumina;
San Diego, CA). Briefly, DNA samples were blunted with a combination of
T4 DNA polymerase, Klenow polymerase, and T4 PNK, and then a single
30-end ‘‘A’’ base was added using Klenow exo (30–50 exo minus). Adapters
provided by Illumina were then ligated to the ends of the modified DNA before
size selection of 200 bp fragments via PAGE extraction. The isolated DNA
was then amplified by 18 cycles of PCR as described. PCR products were
column purified with the QIAquick PCR Purification Kit (QIAGEN), assayed
for quantity and quality with the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies), and diluted to a concentration of 10 nM. The library was sequenced on
an Illumina 1G Genome Analyzer at a concentration of 3–4 pM. The sequencing
output was analyzed using the Genome Analyzer pipeline provided by Illumina.
Sequence tags that aligned uniquely to the mouse genome build MM8 with
zero, one, or two mismatches, according to the ELAND alignment algorithm,
were used for further analysis.
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